Pharmaceutical

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

Jan 9, 2024 - 18:00
HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval
HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.
Read the original article

Tags:

Previous Article

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Next Article

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Promising red-light myopia treatment for children is raising safety concerns among experts

Promising red-light myopia treatment for children is ra...

Feb 3, 2024

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Sanofi’s frexalimab shows early potential in in Phase I...

Jun 1, 2023

WuXi Biologics and Medigene link on T cell engagers for cancer

WuXi Biologics and Medigene link on T cell engagers for...

Aug 11, 2024